Pregnancy and the risk of breast cancer

Endocrine-Related Cancer

Volumn 14, Issue 4, 2007, Pages 907-933

  Britt, Kara ^a,b   Ashworth, Alan ^a   Smalley, Matthew ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE;

BREAST CANCER; BREAST EPITHELIUM; CANCER PREVENTION; CANCER RISK; CELL DIFFERENTIATION; CELL INTERACTION; CELL SUBPOPULATION; EPITHELIUM CELL; GENE EXPRESSION; GENETIC MARKER; HORMONE ACTION; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; LACTATION; MAMMARY GLAND; NONHUMAN; PARITY; PREGNANCY; REVIEW; STEM CELL;

ADULT; ANIMALS; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; INFANT; MAMMARY GLANDS, ANIMAL; MODELS, ANIMAL; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 39149115079     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0137     Document Type: Review

References (269)

1. Abrams TJ, Guzman RC, Swanson SM, Thordarson G, Talamantes F & Nandi S 1998 Changes in the parous rat mammary gland environment are involved in parity-associated protection against mammary carcinogenesis. Anticancer Research 18 4115-4121.
2. Adeyemo O & Jeyakumar H 1993 Plasma progesterone, estradiol-17 beta and testosterone in maternal and cord blood, and maternal human chorionic gonadotropin at parturition. African Journal of Medicine and Medical Sciences 22 55-60.
3. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF & Willett CG 1997 High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79 1203-1210.
4. Albrektsen G, Heuch I, Hansen S & Kvale G 2005 Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. British Journal of Cancer 92 167-175.
5. Anbazhagan R, Osin PP, Bartkova J, Nathan B, Lane EB & Gusterson BA 1998 The development of epithelial phenotypes in the human fetal and infant breast. Journal of Pathology 184 197-206.
6. Ansquer Y, Mandelbrot L, Lehy T, Salomon L, Dhainaut C, Madelenat P, Feldmann G & Walker F 2005 Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features. Anticancer Research 25 4535-4541.
7. Apter D, Reinila M & Vihko R 1989 Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. International Journal of Cancer 44 783-787.
8. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ & Cantor H 2000 Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287 860-864.
9. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE & Lindeman GJ 2006 Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 98 1011-1014.
10. Aupperlee MD, Smith KT, Kariagina A & Haslam SZ 2005 Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146 3577-3588.
11. Balogh GA, Heulings R, Mailo DA, Russo PA, Sheriff F, Russo IH, Moral R & Russo J 2006 Genomic signature induced by pregnancy in the human breast. International Journal of Oncology 28 399-410.
12. Bamberger AM, Milde-Langosch K, Schulte HM & Loning T 2000 Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Hormone Research 54 32-37.
13. Bartow SA 1998 Use of the autopsy to study ontogeny and expression of the estrogen receptor gene in human breast. Journal of Mammary Gland Biology and Neoplasia 3 37-48.
14. Ben-David M 1968 Mechanism of induction of mammary differentiation is Sprague-Dawley female rats by perphenazine. Endocrinology 83 1217-1223.
15. Bern HA, Mills KT, Hatch DL, Ostrander PL & Iguchi T 1992 Altered mammary responsiveness to estradiol and progesterone in mice exposed neonatally to diethylstilbestrol. Cancer Letters 63 117-124.
16. Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB & Henderson BE 1985 Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. Journal of the National Cancer Institute 74 741-745.
17. Bjornstrom L & Sjoberg M 2005 Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Molecular Endocrinology 19 833-842.
18. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM & Chodosh LA 2006 Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Research 66 6421-6431.
19. Booth BW & Smith GH 2006 Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Research 8 R49.
20. Booth D, Haley JD, Bruskin AM & Potten CS 2000 Transforming growth factor-B3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling. International Journal of Cancer 86 53-59.
21. Boulanger CA & Smith GH 2001 Reducing mammary cancer risk through premature stem cell senescence. Oncogene 20 2264-2272.
22. Braun MM, Ahlbom A, Floderus B, Brinton LA & Hoover RN 1995 Effect of twinship on incidence of cancer of the testis, breast, and other sites (Sweden). Cancer Causes and Control 6 519-524.
23. Bridges RS & Byrnes EM 2006 Reproductive experience reduces circulating 17beta-estradiol and prolactin levels during proestrus and alters estrogen sensitivity in female rats. Endocrinology 147 2575-2582.
24. Bridges RS & Hammer RP Jr 1992 Parity-associated alterations of medial preoptic opiate receptors in female rats. Brain Research 578 269-274.
25. Bridges RS, Felicio LF, Pellerin LJ, Stuer AM & Mann PE 1993 Prior parity reduces post-coital diurnal and nocturnal prolactin surges in rats. Life Sciences 53 439-445.
26. Brinton LA, Schairer C, Hoover RN & Fraumeni JF Jr 1988 Menstrual factors and risk of breast cancer. Cancer Investigation 6 245-254.
27. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L & Hoover RN 1995 Oral contraceptives and breast cancer risk among younger women. Journal of the National Cancer Institute 87 827-835.
28. Brisken C, Park S, Vass T, Lydon JP, O'Malley BW & Weinberg RA 1998 A paracrine role for the epithelial progesterone receptor in mammary gland development. PNAS 95 5076-5081.
29. Britton JA, Gammon MD, Schoenberg JB, Stanford JL, Coates RJ, Swanson CA, Potischman N, Malone KE, Brogan DJ, Daling JR et al. 2002 Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. American Journal of Epidemiology 156 507-516.
30. Cairns J 2006 Cancer and the immortal strand hypothesis. Genetics 174 1069-1072.
31. Cardiff RD 1996 The biology of mammary transgenes: five rules. Journal of Mammary Gland Biology and Neoplasia 1 61-73.
32. Cardiff RD & Wellings SR 1999 The comparative pathology of human and mouse mammary glands. Journal of Mammary Gland Biology and Neoplasia 4 105-122.
33. Chu S & Fuller PJ 1997 Identification of a splice variant of the rat estrogen receptor beta gene. Molecular and Cellular Endocrinology 132 195-199.
34. Ciarloni L, Mallepell S & Brisken C 2007 Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. PNAS 104 5455-5460.
35. Clarke RB, Howell A, Potten CS & Anderson E 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research 57 4987-4991.
36. Clarke RB, Spence K, Anderson E, Howell A, Okano H & Potten CS 2005 A putative human breast stem cell population is enriched for steroid receptor-positive cells. Developmental Biology 277 443-456.
37. Colditz GA, Rosner BA, Chen WY, Holmes MD & Hankinson SE 2004 Risk factors for breast cancer according to estrogen and progesterone receptor status. Journal of the National Cancer Institute 96 218-228.
38. Coleman S, Silberstein GB & Daniel CW 1988 Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor. Developmental Biology 127 304-315.
39. Conneely OM, Mulac-Jericevic B & Lydon JP 2003 Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 68 771-778.
40. Cotterchio M, Kreiger N, Theis B, Sloan M & Bahl S 2003 Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiology, Biomarkers and Prevention 12 1053-1060.
41. Couse JF & Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocrine Reviews 20 358-417.
42. Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C et al. 2005 Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer 117 988-991.
43. Curtis Hewitt S, Couse JF & Korach KS 2000 Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Research 2 345-352.
44. Cuzin F & Jacob F 1965 Existence in Escherichia coli of a segregation genetic unit formed from different replicons. Comptes Rendus Hebdomadaires des Séances de l'Académie des Sciences. Série D: Sciences Naturelles 260 5411-5414.
45. Daling JR, Malone KE, Voigt LF, White E & Weiss NS 1994 Risk of breast cancer among young women: relationship to induced abortion. Journal of the National Cancer Institute 86 1584-1592.
46. Daling JR, Brinton LA, Voigt LF, Weiss NS, Coates RJ, Malone KE, Schoenberg JB & Gammon M 1996 Risk of breast cancer among white women following induced abortion. American Journal of Epidemiology 144 373-380.
47. Dao MA, Hwa J & Nolta JA 2002 Molecular mechanism of transforming growth factor beta-mediated cell-cycle modulation in primary human CD34(+) progenitors. Blood 99 499-506.
48. D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA et al. 2002 Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Molecular Endocrinology 16 2034-2051.
49. DiAugustine RP, Petrusz P, Bell GI, Brown CF, Korach KS, McLachlan JA & Teng CT 1988 Influence of estrogens on mouse uterine epidermal growth factor precursor protein and messenger ribonucleic acid. Endocrinology 122 2355-2363.
50. Dontu G, Liu S & Wicha MS 2005 Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Reviews 1 207-213.
51. Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, Campbell WS, Franz C, Kahle L & Taylor PR 1995 Relationships of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women. Cancer Epidemiology, Biomarkers and Prevention 4 381-386.
52. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P et al. 2005 Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. Journal of Clinical Oncology 23 7491-7496.
53. Ekbom A, Trichopoulos D, Adami HO, Hsieh CC & Lan SJ 1992 Evidence of prenatal influences on breast cancer risk. Lancet 340 1015-1018.
54. Eliassen AH, Tworoger SS & Hankinson SE 2007 Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. International Journal of Cancer 120 1536-1541.
55. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S & Osborne CK 2000 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. International Journal of Cancer 89 111-117.
56. Emerman JT, Leahy M, Gout PW & Bruchovsky N 1985 Elevated growth hormone levels in sera from breast cancer patients. Hormone and Metabolic Research 17 421-424.
57. Erlandsson G, Montgomery SM, Cnattingius S & Ekbom A 2003 Abortions and breast cancer: record-based case-control study. International Journal of Cancer 103 676-679.
58. Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL & Barcellos-Hoff MH 2005 Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. American Journal of Pathology 167 409-417.
59. Fendrick JL, Raafat AM & Haslam SZ 1998 Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse. Journal of Mammary Gland Biology and Neoplasia 3 7-22.
60. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ & West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 1747-1749.
61. Filardo EJ 2002 Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. Journal of Steroid Biochemistry and Molecular Biology 80 231-238.
62. Filardo EJ, Quinn JA, Bland KI & Frackelton AR Jr 2000 Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Molecular Endocrinology 14 1649-1660.
63. Fisher CR, Graves KH, Parlow AF & Simpson ER 1998 Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. PNAS 95 6965-6970.
64. Foley J, Dann P, Hong J, Cosgrove J, Dreyer B, Rimm D, Dunbar M, Philbrick W & Wysolmerski J 2001 Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Development 128 513-525.
65. Ford D, Easton DF, Bishop DT, Narod SA & Goldgar DE 1994 Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343 692-695.
66. Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M & Gustafsson JA 2002 Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. PNAS 99 15578-15583.
67. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J et al. 2004 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clinical Cancer Research 10 2029-2034.
68. Gallego MI, Binait N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA & Hennighausen L 2001 Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Developmental Biology 229 163-175.
69. van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, Bruhn L & Grosschedl R 1994 Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes and Development 8 2691-2703.
70. Geschickter CF, Lewis D & Hartman CG 1934 Tumors of the breast related to the oestrin hormone. American Journal of Cancer 21 828-859.
71. Ginger MR, Gonzalez-Rimbau MF, Gay JP & Rosen JM 2001 Persistent changes in gene expression induced by estrogen and progesterone in the rat mammary gland. Molecular Endocrinology 15 1993-2009.
72. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R & Bieche I 2003 Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clinical Cancer Research 9 1259-1266.
73. Girault I, Bieche I & Lidereau R 2006 Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54 342-351.
74. Goldacre MJ, Kurina LM, Seagroatt V & Yeates D 2001 Abortion and breast cancer: a case-control record linkage study. Journal of Epidemiology and Community Health 55 336-337.
75. Gross GE, Clark GM, Chamness GC & McGuire WL 1984 Multiple progesterone receptor assays in human breast cancer. Cancer Research 44 836-840.
76. Group EBCTC 1992a Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339 71-85.
77. Group EBCTC 1992b Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339 1-15.
78. Group EBCTC 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 1451-1467.
79. Grubbs CJ, Juliana MM & Whitaker LM 1988 Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in rats. Anticancer Research 8 113-117.
80. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA & Kuperwasser C 2007 Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Research 67 2062-2071.
81. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X & Nandi S 1999 Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. PNAS 96 2520-2525.
82. Hall JM & McDonnell DP 2005 Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Molecular Interventions 5 343-357.
83. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA & Struewing JP 2002 Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history. Epidemiology 13 255-261.
84. Haslam SZ 1989 The ontogeny of mouse mammary gland responsiveness to ovarian steroid hormones. Endocrinology 125 2766-2772.
85. Haslam SZ & Nummy KA 1992 The ontogeny and cellular distribution of estrogen receptors in normal mouse mammary gland. Journal of Steroid Biochemistry and Molecular Biology 42 589-595.
86. Haslam SZ & Shyamala G 1980 Progesterone receptors in normal mammary gland: receptor modulations in relation to differentiation. Journal of Cell Biology 86 730-737.
87. Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, Mittendorf R, Robboy SJ, Hyer M, Cowan CM, Adam E et al. 1998 Cancer risk in women exposed to diethylstilbestrol in utero. Journal of the American Medical Association 280 630-634.
88. Heery DM, Kalkhoven E, Hoare S & Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 733-736.
89. Helmrich SP, Shapiro S, Rosenberg L, Kaufman DW, Slone D, Bain C, Miettinen OS, Stolley PD, Rosenshein NB, Knapp RC et al. 1983 Risk factors for breast cancer. American Journal of Epidemiology 117 35-45.
90. Henderson BE & Feigelson HS 2000 Hormonal carcinogenesis. Carcinogenesis 21 427-433.
91. Henderson BE, Powell D, Rosario I, Keys C, Hanisch R, Young M, Casagrande J, Gerkins V & Pike MC 1974 An epidemiologic study of breast cancer. Journal of the National Cancer Institute 53 609-614.
92. Hennighausen L & Robinson GW 2001 Signaling pathways in mammary gland development. Developmental Cell 1 467-475.
93. Hens JR & Wysolmerski JJ 2005 Key stages of mammary gland development: molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Research 7 220-224.
94. Horwich A & Swerdlow AJ 2004 Second primary breast cancer after Hodgkin's disease. British Journal of Cancer 90 294-298.
95. Horwitz KB & McGuire WL 1975 Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189 726-727.
96. Hovey RC, Trott JF & Vonderhaar BK 2002 Establishing a framework for the functional mammary gland: from endocrinology to morphology. Journal of Mammary Gland Biology and Neoplasia 7 17-38.
97. Hsieh CC, Trichopoulos D, Katsouyanni K & Yuasa S 1990 Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. International Journal of Cancer 46 796-800.
98. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 96.
99. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS & Moorman PG 2000 Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. American Journal of Epidemiology 151 703-714.
100. Humphreys RC, Lydon JP, O'Malley BW & Rosen JM 1997 Use of PRKO mice to study the role of progesterone in mammary gland development. Journal of Mammary Gland Biology and Neoplasia 2 343-354.
101. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE & Nicholson RI 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 81-93.
102. Ingram DM, Nottage EM & Roberts AN 1990 Prolactin and breast cancer risk. Medical Journal of Australia 153 469-473.
103. Jacquemier JD, Hassoun J, Torrente M & Martin PM 1990 Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages - immunohistochemical study of 107 cases. Breast Cancer Research and Treatment 15 109-117.
104. Janerich DT & Hoff MB 1982 Evidence for a crossover in breast cancer risk factors. American Journal of Epidemiology 116 737-742.
105. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E et al. 1999 Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354 1846-1850.
106. Jones EF & Forrest JD 1992 Underreporting of abortion in surveys of US women: 1976 to 1988. Demography 29 113-126.
107. Kariagina A, Aupperlee MD & Haslam SZ 2007 Progesterone receptor isoforms and proliferation in the rat mammary gland during development. Endocrinology 148 2723-2736.
108. Kass L, Durando M, Ramos JG, Varayoud J, Powell CE, Luque EH & Munoz-de-Toro M 2004 Association of increased estrogen receptor beta2 expression with parity-induced alterations in the rat mammary gland. Journal of Steroid Biochemistry and Molecular Biology 91 29-39.
109. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR et al. 2002 Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine 346 1609-1615.
110. Keeling JW, Ozer E, King G & Walker F 2000 Oestrogen receptor alpha in female fetal, infant, and child mammary tissue. Journal of Pathology 191 449-451.
111. Kelsey JL, Gammon MD & John EM 1993 Reproductive factors and breast cancer. Epidemiologic Reviews 15 36-47.
112. Kenney NJ, Huang RP, Johnson GR, Wu JX, Okamura D, Matheny W, Kordon E, Gullick WJ, Plowman G, Smith GH et al. 1995 Detection and location of amphiregulin and Cripto-1 expression in the developing postnatal mouse mammary gland. Molecular Reproduction and Development 41 277-286.
113. Kenney NJ, Smith GH, Lawrence E, Barrett JC & Salomon DS 2001 Identification of stem cell units in the terminal end bud and duct of the mouse mammary gland. Journal of Biomedicine and Biotechnology 1 133-143.
114. Kenney NJ, Bowman A, Korach KS, Barrett JC & Salomon DS 2003 Effect of exogenous epidermal-like growth factors on mammary gland development and differentiation in the estrogen receptor-alpha knockout (ERKO) mouse. Breast Cancer Research and Treatment 79 161-173.
115. Kimble J 1981 Alterations in cell lineage following laser ablation of cells in the somatic gonad of Caenorhabditis elegans. Developmental Biology 87 286-300.
116. Kleinberg DL, Feldman M & Ruan W 2000 IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis. Journal of Mammary Gland Biology and Neoplasia 5 7-17.
117. Kos M, O'Brien S, Flouriot G & Gannon F 2000 Tissue-specific expression of multiple mRNA variants of the mouse estrogen receptor alpha gene. FEBS Letters 477 15-20.
118. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA & Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor beta. PNAS 95 15677-15682.
119. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM & Karlsson S 1993 Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. PNAS 90 770-774.
120. Kushner PJ, Agard D, Feng WJ, Lopez G, Schiau A, Uht R, Webb P & Greene G 2000 Oestrogen receptor function at classical and alternative response elements. Novartis Foundation Symposium 230 20-40.
121. Kvale G & Heuch I 1988 Menstrual factors and breast cancer risk. Cancer 62 1625-1631.
122. Kwa HG, Cleton F, Bulbrook RD, Wang DY & Hayward JL 1981 Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth. International Journal of Cancer 28 31-34.
123. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M & Adami HO 1994 Transient increase in the risk of breast cancer after giving birth. New England Journal of Medicine 331 5-9.
124. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D & Adami HO 1998 Parity, age at first birth and the risk of carcinoma in situ of the breast. International Journal of Cancer 77 330-332.
125. Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I & Tokuoka S 2003 Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiation Research 160 707-717.
126. Lansdorp PM 2007 Immortal strands? Give me a break. Cell 129 1244-1247.
127. Lark KG & Bird RE 1965 Segregation of the conserved units of DNA in Escherichia coli. PNAS 54 1444-1450.
128. Lark KG, Consigli RA & Minocha HC 1966 Segregation of sister chromatids in mammalian cells. Science 154 1202-1205.
129. Leavitt WW, Chen TJ & Allen TC 1977 Regulation of progesterone receptor formation by estrogen action. Annals of the New York Academy of Sciences 286 210-225.
130. Lin CY, Strom A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J et al. 2007 Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Research 9 R25.
131. Lindefors-Harris BM, Eklund G, Adami HO & Meirik O 1991 Response bias in a case-control study: analysis utilizing comparative data concerning legal abortions from two independent Swedish studies. American Journal of Epidemiology 134 1003-1008.
132. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT & Perou CM 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathology 19 264-271.
133. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M & Olsson H 1998 Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 310-319.
134. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A & Lee DC 1999 Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126 2739-2750.
135. Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC & Watson PH 1998 Estrogen receptor-beta mRNA variants in human and murine tissues. Molecular and Cellular Endocrinology 138 199-203.
136. Lu D & Giguère V 2001 Requirement of Ras-dependent pathways for activation of the transforming growth factor beta3 promoter by estradiol. Endocrinology 142 751-759.
137. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM & O'Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes and Development 9 2266-2278.
138. Ma H, Bernstein L, Pike MC & Ursin G 2006 Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Research 8 R43.
139. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG & Yuasa S 1970 Age at first birth and breast cancer risk. Bulletin of the World Health Organization 43 209-221.
140. MacMahon B, Trichopoulos D, Brown J, Andersen AP, Cole P, deWaard F, Kauraniemi T, Polychronopoulou A, Ravnihar B, Stormby N et al. 1982 Age at menarche, urine estrogens and breast cancer risk. International Journal of Cancer 30 427-431.
141. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D & Ando S 2004 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. Journal of Biological Chemistry 279 27008-27016.
142. Mailleux AA, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N, Kato S, Dickson C, Thiery JP & Bellusci S 2002 Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development 129 53-60.
143. Mallepell S, Krust A, Chambon P & Brisken C 2006 Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. PNAS 103 2196-2201.
144. Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK et al. 2002 The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Annals of Epidemiology 12 213-221.
145. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
146. Masood S 1992 Estrogen and progesterone receptors in cytology: a comprehensive review. Diagnostic Cytopathology 8 475-491.
147. McCredie MR, Dite GS, Southey MC, Venter DJ, Giles GG & Hopper JL 2003 Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. British Journal of Cancer 89 1661-1663.
148. McDonnell DP & Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296 1642-1644.
149. McKenna NJ, Lanz RB & O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321-344.
150. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL et al. 2007 Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncology 8 26-34.
151. Medina D, Peterson LE, Moraes R & Gay J 2001 Short-term exposure to estrogen and progesterone induces partial protection against N-nitroso-N-methylurea-induced mammary tumorigenesis in Wistar-Furth rats. Cancer Letters 169 1-6.
152. Melbye M, Wohlfahrt J, Olsen JH, Frisch M, Westergaard T, Helweg-Larsen K & Andersen PK 1997 Induced abortion and the risk of breast cancer. New England Journal of Medicine 336 81-85.
153. Meyer ME, Quirin-Stricker C, Lerouge T, Bocquel MT & Gronemeyer H 1992 A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. Journal of Biological Chemistry 267 10882-10887.
154. Michels KB & Willett WC 1996 Does induced or spontaneous abortion affect the risk of breast cancer? Epidemiology 7 521-528.
155. Michels KB, Xue F, Colditz GA & Willett WC 2007 Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Archives of Internal Medicine 167 814-820.
156. Milgrom E, Thi L, Atger M & Baulieu EE 1973 Mechanisms regulating the concentration and the conformation of progesterone receptor(s) in the uterus. Journal of Biological Chemistry 248 6366-6374.
157. Moore DE, Kawagoe S, Davajan V, Mishell DR & Nakamura RM 1978 An in vivo system in man for quantitation of estrogenicity. I. Physiologic changes in binding capacity of serum corticosteroid-binding globulin. American Journal of Obstetrics and Gynecology 130 475-481.
158. Mori T, Bern HA, Mills KT & Young PN 1976 Long-term effects of neonatal steroid exposure on mammary gland development and tumorigenesis in mice. Journal of the National Cancer Institute 57 1057-1062.
159. Moriarty K, Kim KH & Bender JR 2006 Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 147 5557-5563.
160. Morrison SJ, Uchida N & Weissman IL 1995 The biology of hematopoietic stem cells. Annual Review of Cell and Developmental Biology 11 35-71.
161. Mote PA, Johnston JF, Manninen T, Tuohimaa P & Clarke CL 2001 Detection of progesterone receptor forms A and B by immunohistochemical analysis. Journal of Clinical Pathology 54 624-630.
162. Mote PA, Bartow S, Tran N & Clarke CL 2002 Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Research and Treatment 72 163-172.
163. Musey VC, Collins DC, Musey PI, Martino-Saltzman D & Preedy JR 1987 Long-term effect of a first pregnancy on the secretion of prolactin. New England Journal of Medicine 316 229-234.
164. Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M et al. 2007 BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 16 280-292.
165. Nagasawa H, Mori T & Nakajima Y 1980 Long-term effects of progesterone or diethylstilbestrol with or without estrogen after maturity on mammary tumorigenesis in mice. European Journal of Cancer 16 1583-1589.
166. Nagasawa H, Yanai R, Shodono M, Nakamura T & Tanabe Y 1974 Effect of neonatally administered estrogen or prolactin on normal and neoplastic mammary growth and serum estradiol-17 beta level in rats. Cancer Research 34 2643-2646.
167. Nissen-Meyer R 1964a Prophylactic endocrine treatment in carcinoma of the breast. Clinical Radiology 15 152-160.
168. Nissen-Meyer R 1964b 'Prophylactic' ovariectomy and ovarian irradiation in breast cancer. Acta - Unio Internationalis Contra Cancrum 20 527-530.
169. Numan M 1994 The Physiology of Reproduction, Eds E Knobil & JD Neill. New York: Raven Press.
170. Offner H, Adlard K, Zamora A & Vandenbark AA 2000 Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. Journal of Clinical Investigation 105 1465-1472.
171. Osborne CK, Yochmowitz MG, Knight WA III & McGuire WL 1980 The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 2884-2888.
172. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Alfred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
173. Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, Noller KL, Herbst AL, Rao RS, Troisi R et al. 2002 Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Cancer Causes and Control 13 753-758.
174. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M et al. 2002 Estrogen receptor beta in breast cancer. Endocrine-Related Cancer 9 1-13.
175. Parmar H & Cunha GR 2004 Epithelial-stromal interactions in the mouse and human mammary gland in vivo. Endocrine-Related Cancer 11 437-458.
176. Petersen OW, Hoyer PE & van Deurs B 1987 Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Research 47 5748-5751.
177. Pierce DF Jr, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BL & Moses HL 1993 Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes and Development 7 2308-2317.
178. Pike MC, Henderson BE, Casagrande JT, Rosario I & Gray GE 1981 Oral contraceptive use and early abortion as risk factors for breast cancer in young women. British Journal of Cancer 43 72-76.
179. Poola I, Abraham J & Baldwin K 2002 Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Letters 516 133-138.
180. Poola I, Koduri S, Chatra S & Clarke R 2000 Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. Journal of Steroid Biochemistry and Molecular Biology 72 249-258.
181. Poola I & Speirs V 2001 Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology 78 459-469.
182. Potter JD, Cerhan JR, Sellers TA, McGovern PG, Drinkard C, Kushi LR & Folsom AR 1995 Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiology, Biomarkers and Prevention 4 319-326.
183. Raafat AM, Hofseth LJ, Li S, Bennett JM & Haslam SZ 1999 A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: enhanced proliferative response to estrogen in late postmenopausal mice. Endocrinology 140 2570-2580.
184. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F & Nandi S 2001 Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. PNAS 98 11755-11759.
185. Rama S, Suresh Y & Rao AJ 2001 Regulation of telomerase during human placental differentiation: a role for TGFbeta1. Molecular and Cellular Endocrinology 182 233-248.
186. Rando TA 2007 The immortal strand hypothesis: segregation and reconstruction. Cell 129 1239-1243.
187. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ et al. 1992 Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. Journal of Clinical Oncology 10 1284-1291.
188. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK et al. 1999 Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute 91 1475-1479.
189. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, Nolan C & Coombes RC 1991 Estrogen and progesterone receptors in the normal female breast. Cancer Research 51 1817-1822.
190. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL et al. 2001 Prevalence and penetrance of germline BRCAl and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 68 700-710.
191. Roos WP, Christmann M, Fraser ST & Kaina B 2007 Mouse embryonic stem cells are hypersensitive to apoptosis triggered by the DNA damage 0(6)-methylguanine due to high E2F1 regulated mismatch repair. Cell Death and Differentiation 14 1422-1432.
192. Rose DP, Gottardis M & Noonan JJ 1983 Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin. Anticancer Research 3 323-325.
193. Rosner B, Colditz GA & Willett WC 1994 Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. American Journal of Epidemiology 139 819-835.
194. Rothman KJ, MacMahon B, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Trichopoulos D & Yuasa S 1980 Maternal age and birth rank of women with breast cancer. Journal of the National Cancer Institute 65 719-722.
195. Rothschild TC, Boylan ES, Calhoon RE & Vonderhaar BK 1987 Transplacental effects of diethylstilbestrol on mammary development and tumorigenesis in female ACI rats. Cancer Research 47 4508-4516.
196. Rusiecki JA, Holford TR, Zahm SH & Zheng T 2005 Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detection and Prevention 29 419-426.
197. Russo J & Russo IH 1980 Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Research 40 2677-2687.
198. Russo J & Russo IH 1987a Biological and molecular bases of mammary carcinogenesis. Laboratory Investigation 57 112-137.
199. Russo J & Russo IH 1987b Development of the human mammary gland, Eds MD Neville & C Daniel. New York: Plenum Publishing Inc.
200. Russo J & Russo IH 1997 Toward a unified concept of mammary carcinogenesis. Progress in Clinical and Biological Research 396 1-16.
201. Russo IH & Russo J 1998 Role of hormones in mammary cancer initiation and progression. Journal of Mammary Gland Biology and Neoplasia 3 49-61.
202. Russo J, Tay LK & Russo IH 1982 Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Research and Treatment 2 5-73.
203. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR & van Zwieten MJ 1990 Comparative study of human and rat mammary tumorigenesis. Laboratory Investigation 62 244-278.
204. Russo J, Rivera R & Russo IH 1992 Influence of age and parity on the development of the human breast. Breast Cancer Research and Treatment 23 211-218.
205. Russo J, Yang X, Hu YF, Bove BA, Huang Y, Silva ID, Tahin Q, Wu Y, Higgy N, Zekri A et al. 1998 Biological and molecular basis of human breast cancer. Frontiers in Bioscience 3 D944-D960.
206. Russo J, Ao X, Grill C & Russo IH 1999 Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Research and Treatment 53 217-227.
207. Saji S, Jensen EV, Nilsson S, Rylander T, Warner M & Gustafsson JA 2000 Estrogen receptors alpha and beta in the rodent mammary gland. PNAS 97 337-342.
208. Sapino A, Macri L, Gugliotta P, Pacchioni D, Liu YJ, Medina D & Bussolati G 1993 Immunophenotypic properties and estrogen dependency of budding cell structures in the developing mouse mammary gland. Differentiation 55 13-18.
209. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S et al. 2000 Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nature Genetics 24 391-395.
210. Schedin P 2006 Pregnancy-associated breast cancer and metastasis. Nature Reviews. Cancer 6 281-291.
211. Schneider R, Dorn CR & Taylor DO 1969 Factors influencing canine mammary cancer development and postsurgical survival. Journal of the National Cancer Institute 43 1249-1261.
212. Sebastian J, Richards RG, Walker MP, Wiesen JF, Werb Z, Derynck R, Horn YK, Cunha GR & Di Augustine RP 1998 Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell Growth and Differentiation 9 777-785.
213. Secreto FJ, Monroe DG, Dutta S, Ingle JN & Spelsberg TC 2007 Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. Journal of Cellular Biochemistry 101 1125-1147.
214. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ & Visvader JE 2006 Generation of a functional mammary gland from a single stem cell. Nature 439 84-88.
215. Shaikh AA 1971 Estrone and estradiol levels in the ovarian venous blood from rats during the estrous cycle and pregnancy. Biology of Reproduction 5 297-307.
216. Shang Y, Hu X, DiRenzo J, Lazar MA & Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843-852.
217. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL & Walker RA 2002 Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. Journal of Pathology 198 450-457.
218. Shellabarger CJ & Soo VA 1973 Effects of neonatally administered sex steroids on 7,12-dimethylbenz(a) anthracene-induced mammary neoplasia in rats. Cancer Research 33 1567-1569.
219. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
220. Shimada A, Kimura S, Abe K, Nagasaki K, Adachi I, Yamaguchi K, Suzuki M, Nakajima T & Miller LS 1985 Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections. PNAS 82 4803-4807.
221. Shinin V, Gayraud-Morel B, Gomes D & Tajbakhsh S 2006 Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells. Nature Cell Biology 8 677-687.
222. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M et al. 2007 Molecular definition of breast tumor heterogeneity. Cancer Cell 11 259-273.
223. Shoker BS, Jarvis C, Sibson DR, Walker C & Sloane JP 1999 Oestrogen receptor expression in the normal and pre-cancerous breast. Journal of Pathology 188 237-244.
224. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH & Nandi S 2002 Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. Journal of Steroid Biochemistry and Molecular Biology 80 137-148.
225. Sinha DK, Pazik JE & Dao TL 1988 Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. British Journal of Cancer 57 390-394.
226. Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW & Medina D 1998 Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis 19 1573-1581.
227. Sleeman KE, Kendrick H, Ashworth A, Isacke CM & Smalley MJ 2006 CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Research 8 R7.
228. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A & Smalley MJ 2007 Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. Journal of Cell Biology 176 19-26.
229. Smalley M & Ashworth A 2003 Stem cells and breast cancer: a field in transit. Nature Reviews. Cancer 3 832-844.
230. Smith GH 2005 Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands. Development 132 681-687.
231. Smith CL & O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45-71.
232. Speirs V, Skliris GP, Burdall SE & Carder PJ 2002 Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. Journal of Clinical Pathology 55 371-374.
233. Srinivasan K, Strickland P, Valdes A, Shin GC & Hinck L 2003 Netrin-1/neogenin interaction stabilizes multipotent progenitor cap cells during mammary gland morphogenesis. Developmental Cell 4 371-382.
234. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, Bell AK, Ferrier RK, Sandilands GP & Gusterson BA 2004 Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Research 6 R75-R91.
235. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC & Werb Z 2005 Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 132 3923-3933.
236. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI & Eaves CJ 2006 Purification and unique properties of mammary epithelial stem cells. Nature 439 993-997.
237. Su Y, Simmen FA, Xiao R & Simmen RC 2007 Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiological Genomics 30 8-16.
238. Swanson SM & Unterman TG 2002 The growth hormone-deficient spontaneous dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 23 977-982.
239. Tang MT, Weiss NS, Daling JR & Malone KE 2000 Case-control differences in the reliability of reporting a history of induced abortion. American Journal of Epidemiology 151 1139-1143.
240. Thompson WD & Janerich DT 1990 Maternal age at birth and risk of breast cancer in daughters. Epidemiology 1 101-106.
241. Thordarson G, Jin E, Guzman RC, Swanson SM, Nandi S & Talamantes F 1995 Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia? Carcinogenesis 16 2847-2853.
242. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M & Akiba S 1994 Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiation Research 138 209-223.
243. Trichopoulos D, Hsieh CC, MacMahon B, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG & Yuasa S 1983 Age at any birth and breast cancer risk. International Journal of Cancer 31 701-704.
244. Tryggvadottir L, Olafsdottir EJ, Gudlaugsdottir S, Thorlacius S, Jonasson JG, Tulinius H & Eyfjord JE 2003 BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Research 5 R121-R128.
245. Ursin G, Bernstein L, Wang Y, Lord SJ, Deapen D, Liff JM, Norman SA, Weiss LK, Daling JR, Marchbanks PA et al. 2004 Reproductive factors and risk of breast carcinoma in a study of white and African-American women. Cancer 101 353-362.
246. Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, Daling JR, Norman SA, Liff JM, Marchbanks PA et al. 2005 Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. British Journal of Cancer 93 364-371.
247. Vandenberg LN, Wadia PR, Schaeberle CM, Rubin BS, Sonnenschein C & Soto AM 2006 The mammary gland response to estradiol: monotonie at the cellular level, non-monotonic at the tissue-level of organization? Journal of Steroid Biochemistry and Molecular Biology 101 263-274.
248. Visvader JE & Lindeman GJ 2006 Mammary stem cells and mammopoiesis. Cancer Research 66 9798-9801.
249. de Waard F & Trichopoulos D 1988 A unifying concept of the aetiology of breast cancer. International Journal of Cancer 41 666-669.
250. Watson J, Anderson FB, Alam M, O'Grady JE & Heald PJ 1975 Plasma hormones and pituitary luteinizing hormone in the rat during the early stages of pregnancy and after post-coital treatment with tamoxifen (ICI 46,474). Journal of Endocrinology 65 7-17.
251. Weiss HA, Potischman NA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE & Schoenberg JB 1997 Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology 8 181-187.
252. Wellings SR 1980a A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathology, Research and Practice 166 515-535.
253. Wellings SR 1980b Development of human breast cancer. Advances in Cancer Research 31 287-314.
254. Wellings SR, Jensen HM & Marcum RG 1975 An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. Journal of the National Cancer Institute 55 231-273.
255. Welsch CW & Nagasawa H 1977 Prolactin and murine mammary tumorigenesis: a review. Cancer Research 37 951-963.
256. Wicha MS 2006 Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis. Breast Cancer Research 8 109.
257. Wiesen JF, Young P, Werb Z & Cunha GR 1999 Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 126 335-344.
258. Williams JM & Daniel CW 1983 Mammary ductal elongation: differentiation of myoepithelium and basal lamina during branching morphogenesis. Developmental Biology 97 274-290.
259. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA & Potten CS 1991 Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. International Journal of Cancer 48 206-210.
260. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC & Pike MC 2002 Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 23 1491-1496.
261. Yang J, Yoshizawa K, Nandi S & Tsubura A 1999 Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. Carcinogenesis 20 623-628.
262. Yang H, Kyo S, Takatura M & Sun L 2001 Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth and Differentiation 12 119-127.
263. Yarden RI, Lauber AH, El-Ashry D & Chrysogelos SA 1996 Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 137 2739-2747.
264. Yehiely F, Moyano JV, Evans JR, Nielsen TO & Cryns VL 2006 Deconstructing the molecular portrait of basal-like breast cancer. Trends in Molecular Medicine 12 537-544.
265. Yoo KY, Tajima K, Miura S, Takeuchi T, Hirose K, Risch H & Dubrow R 1997 Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. American Journal of Epidemiology 146 307-314.
266. Yoshida H & Fukunishi R 1978 Effect of neonatal administration of sex steroids on 7,12-dimethylbenz [a]anthracene-induced mammary carcinoma and dysplasia in female Sprague-Dawley rats. Gann 69 627-631.
267. Young S & Hallowes RC 1973 Tumours of the mammary gland. IARC Scientific Publications 31-73.
268. Yuan JM, Yu MC, Ross RK, Gao YT & Henderson BE 1988 Risk factors for breast cancer in Chinese women in Shanghai. Cancer Research 48 1949-1953.
269. Zeps N, Bentel JM, Papadimitriou JM, D'Antuono MF & Dawkins HJ 1998 Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation 62 221-226.